最新ニュース Penumbra (NYSE:PEN) 株価情報

PENUMBRA INC

Penumbra

Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are sold to hospitals and are developed for use by specialist physicians. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. It operates as one reportable segment and its business activity consists of the design, development, manufacturing and marketing of inventive medical products.

Movers

Trading Ideas

BIMI

DALN

FFIE

FGEN

GRPN

JTAI

LMND

MGNX

NUZE

PITA

PMEC

POWL

TBIO

TIVC

アドバンスト マイクロ デバイセズ社 (NASDAQ:AMD) の株は、予想を上回る第2四半期決算を受けて本日のプレマーケット取引で急騰している。

AMD株価上昇　決算を受けて

Penumbra Inc

Pendle - United States Dollar

Penguin Solutions, Inc. - Ordinary Shares

Penguin Solutions Inc

Peninsula Energy Ltd

PENINSULA ENERGY LTD by Peninsula Energy Ltd.

PENN Entertainment Inc

PENTAMASTER CORP BHD by PENTAMASTER CORP BHD.

PENNANT INTL GRP PLC by Pennant International Group PLC

Penumbra's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>) short percent of float has risen 4.22% since its last report. The company recently reported that it has 1.57 million shares sold short, which is 5.68% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.35 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Penumbra Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746626430_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Penumbra has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Penumbra's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Penumbra's peer group average for short interest as a percentage of float is 4.09%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

What's Driving the Market Sentiment Around Penumbra?

<h3>Gainers</h3>
<ul>
<li>Azitra (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AZTR#AMEX">AZTR</a>) stock rose 35.0% to $0.41 during Thursday's after-market session. The company's market cap stands at $6.1 million. </li>
<li>Alector (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALEC#NASDAQ">ALEC</a>) shares moved upwards by 9.11% to $1.28. The company's market cap stands at $126.5 million. </li>
<li>Xtant Medical Hldgs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/XTNT#AMEX">XTNT</a>) stock rose 8.33% to $0.52. The market value of their outstanding shares is at $72.4 million. </li>
<li>Mobile-health Network (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDR#NASDAQ">MNDR</a>) shares rose 7.63% to $1.55. The market value of their outstanding shares is at $6.7 million. </li>
<li>Penumbra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>) shares rose 6.75% to $318.4. The market value of their outstanding shares is at $12.3 billion. The company's, Q1 earnings came out yesterday. </li>
<li>Ovid Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OVID#NASDAQ">OVID</a>) shares increased by 6.59% to $0.36. The market value of their outstanding shares is at $25.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>SenesTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNES#NASDAQ">SNES</a>) shares declined by 8.3% to $2.0 during Thursday's after-market session. The market value of their outstanding shares is at $3.4 million. </li>
<li>IGC Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IGC#AMEX">IGC</a>) shares decreased by 7.59% to $0.29. The company's market cap stands at $23.1 million. </li>
<li>Processa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCSA#NASDAQ">PCSA</a>) shares fell 7.04% to $0.22. The company's market cap stands at $1.1 million. </li>
<li>Senti Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTI#NASDAQ">SNTI</a>) shares declined by 6.52% to $4.59. The market value of their outstanding shares is at $119.3 million. </li>
<li>CNS Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) stock decreased by 5.96% to $0.98. The market value of their outstanding shares is at $2.8 million. </li>
<li>VolitionRX (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VNRX#AMEX">VNRX</a>) stock declined by 5.92% to $0.46. The market value of their outstanding shares is at $45.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALEC

AZTR

CNSP

MNDR

OVID

PCSA

SNES

SNTI

VNRX

XTNT

12 Health Care Stocks Moving In Thursday's After-Market Session

Penumbra Inc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>) stock is trading higher after the company reported better-than-expected&nbsp;first-quarter 2025 earnings and <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/n44964153/penumbra-inc-reports-first-quarter-2025-financial-results" rel="noreferrer noopener">reaffirmed the 2025 forecast</a>.
The medical device company reported:
<ul>
<li>Sales of $324.1 million, up 16.3% year over year (+16.9% in constant currency) and beating the consensus of $315.66 million.</li>
<li>Adjusted EPS of 83 cents, beating the&nbsp;<a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">consensus of 67 cents</a>.</li>
</ul>
Revenue from global thrombectomy products grew to&nbsp;$226.5&nbsp;million in the first quarter of 2025, an increase of 20.7%, or 21.2%, in constant currency.
<ul>
<li>U.S. Thrombectomy revenue of&nbsp;$187.9 million increased 25.0% year over year.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/25/04/44977669/pepsico-ceo-warns-of-tariffs-led-increase-in-supply-chain-costs-cuts-annual-profit-outlook" rel="noreferrer noopener">PepsiCo CEO Warns Of Tariffs Led &#8216;Increase In Supply Chain Costs,&#8217; Cuts Annual Profit Outlook</a>
Revenue from global embolization and access products grew 7.3% of 8.1% in constant currency to&nbsp;$97.6&nbsp;million.
<ul>
<li>U.S. embolization and access products revenue increased 16.2% to 68.97 million</li>
</ul>
Operating income reached $40.4 million. Q1 net income was $39.2 million and adjusted EBITDA of $59.6 million, with 12.1% and 18.4% margins, respectively.
Guidance: Penumbra reaffirms its fiscal year 202 sales guidance of $1.34 billion to $1.36 billion, versus the consensus of $1.35 billion.
<ul>
<li>The company is increasing guidance for the U.S. Thrombectomy franchise growth to 20% to 21% year over year <a href="https://www.benzinga.com/25/02/43829643/stroke-device-maker-penumbra-stock-surges-on-earnings-beat-upbeat-2025-outlook-analysts-boost-price-forecasts" target="_blank" rel="noreferrer noopener">from 19% to 20%</a>.</li>
<li>It reaffirms guidance for gross margin expansion of at least 100 basis points in 2025, to more than 67% for the full year, and operating margin expansion to 13%-14% of revenue for 2025.</li>
</ul>
William Blair notes that since the company manufactures in the U.S. and gets 75% of its raw materials domestically, it expects little impact from tariffs this year. Also, with nearly 80% of its revenue coming from the U.S., the company has left out a $5 million contribution from China in its full-year outlook.
&#8220;We believe Penumbra is one of the most well-insulated companies from ongoing tariff dynamics across our coverage,&#8221; analyst Margaret Kaczor Andrew writes.
William Blair maintains an Outperform rating for Penumbra stock.
&#8220;Looking at the momentum thus far and management's thoughtful approach to guidance, we see further room for share upside as the company executes on its four-pronged strategy,&#8221; analyst Andrew adds.
Analyst Reaction:
<ul>
<li>Stifel maintains a Buy rating on Penumbra, raising the price target from $301 to $318.</li>
<li>Truist Securities maintains a Buy rating on Penumbra, raising the price target from $315 to $330.</li>
<li>Wells Fargo maintains a rating of Penumbra as Overweight, raising the price target from $305 to $315.</li>
<li>Baird maintains Penumbra with an Outperform, raising the price target from $316 to $325.</li>
<li>UBS maintains a Buy rating on Penumbra and raises the price target from $320 to $330.</li>
</ul>
Price Action: PEN stock is up 6.37% at $296.53 at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44976464/alaska-air-hit-by-demand-dip-in-q1-loss-skips-fy25-guidance-update-amid-uncertainty" target="_blank" rel="noreferrer noopener">Alaska Air Hit By Demand Softness In Q1, Skips Annual Outlook Citing Macro Uncertainty</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Earnings

Large Cap

News

Guidance

Health Care

Price Target

Analyst Ratings

General

Penumbra Among Well-Insulated Companies From Ongoing Tariff Dynamics, Says Analyst

RBC Capital analyst Shagun Singh maintains Penumbra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>) with a Outperform and raises the price target from $315 to $330.

RBC Capital Maintains Outperform on Penumbra, Raises Price Target to $330

UBS analyst Priya Sachdeva maintains Penumbra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>) with a Buy and raises the price target from $320 to $330.

UBS Maintains Buy on Penumbra, Raises Price Target to $330

Truist Securities analyst David Rescott maintains Penumbra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>) with a Buy and raises the price target from $315 to $330.

Truist Securities Maintains Buy on Penumbra, Raises Price Target to $330

Stifel analyst Mathew Blackman maintains Penumbra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>) with a Buy and raises the price target from $301 to $318.

Stifel Maintains Buy on Penumbra, Raises Price Target to $318

WIIM

Penumbra shares are trading higher after the company reported better-than-expected Q1 financial results. Additionally, Baird and Wells Fargo raised their respective price targets on the stock.

Wells Fargo analyst Larry Biegelsen maintains Penumbra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>) with a Overweight and raises the price target from $305 to $315.

Wells Fargo Maintains Overweight on Penumbra, Raises Price Target to $315

Providing a diverse range of perspectives from bullish to bearish, 12 analysts have published ratings on Penumbra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>) in the last three months.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Penumbra, revealing an average target of $313.83, a high estimate of $340.00, and a low estimate of $260.00. Marking an increase of 9.98%, the current average surpasses the previous average price target of $285.36. 
<img src="https://www.benzinga.com/files/images/story/2025/1745499620_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A comprehensive examination of how financial experts perceive Penumbra is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;David Rescott &#x7C;Baird &#x7C;Raises &#x7C;Outperform &#x7C; $325.00&#x7C;$316.00 &#x7C; 
&#x7C;David Rescott &#x7C;Truist Securities &#x7C;Lowers &#x7C;Buy &#x7C; $315.00&#x7C;$325.00 &#x7C; 
&#x7C;Travis Steed &#x7C;B of A Securities &#x7C;Announces &#x7C;Buy &#x7C; $320.00&#x7C;- &#x7C; 
&#x7C;Robert Marcus &#x7C;JP Morgan &#x7C;Raises &#x7C;Overweight &#x7C; $285.00&#x7C;$230.00 &#x7C; 
&#x7C;David Rescott &#x7C;Truist Securities &#x7C;Raises &#x7C;Buy &#x7C; $325.00&#x7C;$285.00 &#x7C; 
&#x7C;Shagun Singh &#x7C;RBC Capital &#x7C;Raises &#x7C;Outperform &#x7C; $313.00&#x7C;$285.00 &#x7C; 
&#x7C;Jason Mills &#x7C;Canaccord Genuity &#x7C;Raises &#x7C;Buy &#x7C; $340.00&#x7C;$323.00 &#x7C; 
&#x7C;Priya Sachdeva &#x7C;UBS &#x7C;Raises &#x7C;Buy &#x7C; $320.00&#x7C;$305.00 &#x7C; 
&#x7C;Larry Biegelsen &#x7C;Wells Fargo &#x7C;Raises &#x7C;Overweight &#x7C; $305.00&#x7C;$275.00 &#x7C; 
&#x7C;Matt O'Brien &#x7C;Piper Sandler &#x7C;Raises &#x7C;Overweight &#x7C; $330.00&#x7C;$250.00 &#x7C; 
&#x7C;Kallum Titchmarsh &#x7C;Morgan Stanley &#x7C;Raises &#x7C;Equal-Weight &#x7C; $260.00&#x7C;$240.00 &#x7C; 
&#x7C;David Rescott &#x7C;Baird &#x7C;Raises &#x7C;Outperform &#x7C; $328.00&#x7C;$305.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Penumbra. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Penumbra compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Penumbra's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Penumbra's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PEN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Penumbra analyst ratings.</a>
<h2>All You Need to Know About Penumbra</h2>
Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are sold to hospitals and are developed for use by specialist physicians. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. It operates as one reportable segment and its business activity consists of the design, development, manufacturing and marketing of inventive medical products.
<h3>Penumbra: Delving into Financials</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3M period, Penumbra showcased positive performance, achieving a revenue growth rate of 10.83% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Penumbra's net margin is impressive, surpassing industry averages. With a net margin of 10.68%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Penumbra's ROE excels beyond industry benchmarks, reaching 2.99%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Penumbra's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 2.24%, the company showcases efficient use of assets and strong financial health.
Debt Management: Penumbra's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.19.
<h2>What Are Analyst Ratings?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down Penumbra: 12 Analysts Share Their Views

Baird analyst David Rescott maintains Penumbra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>) with a Outperform and raises the price target from $316 to $325.

Baird Maintains Outperform on Penumbra, Raises Price Target to $325

Penumbra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>) affirms FY2025 sales outlook from $1.34 billion-$1.36 billion to $1.34 billion-$1.36 billion vs $1.35 billion estimate.

Penumbra Affirms FY2025 Sales Guidance of $1.34B-$1.36B vs $1.35B Est

Penumbra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>) reported quarterly earnings of $0.83 per share which beat the analyst consensus estimate of $0.67 by 23.88 percent. This is a 102.44 percent increase over earnings of $0.41 per share from the same period last year. The company reported quarterly sales of $324.14 million which beat the analyst consensus estimate of $315.66 million by 2.69 percent. This is a 16.32 percent increase over sales of $278.65 million the same period last year.

Earnings Beats

Penumbra Q1 Adj. EPS $0.83 Beats $0.67 Estimate, Sales $324.14M Beat $315.66M Estimate

AMTB

ASGN

BANC

BPOP

BRKL

BWFG

CACI

CBAN

CHDN

CHKP

COOP

CSLR

CVLG

New Oriental Education & Technology Group

EGBN

EPRT

GATX

GLPG

GSHD

HBNC

HCSG

IMAX

INBK

KALU

KREF

LRCX

MTDR

ODFL

ORLY

OSBC

OTIS

PLXS

PTEN

SEIC

Earnings Scheduled For April 23, 2025

Penumbra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>) is preparing to release its quarterly earnings on Wednesday, 2025-04-23. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Penumbra to report an earnings per share (EPS) of $0.67.
The announcement from Penumbra is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Overview of Past Earnings</h3>
Last quarter the company beat EPS by $0.08, which was followed by a 12.03% increase in the share price the next day.
Here's a look at Penumbra's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.89</td>
<td>0.69</td>
<td>0.56</td>
<td>0.38</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.97</td>
<td>0.85</td>
<td>0.64</td>
<td>0.41</td>
</tr>
<tr>
<td>Price Change %</td>
<td>12.0%</td>
<td>8.0%</td>
<td>-3.0%</td>
<td>-3.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745337697_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Penumbra were trading at $270.64 as of April 21. Over the last 52-week period, shares are up 32.52%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analyst Insights on Penumbra</h3>
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Penumbra.
Analysts have given Penumbra a total of 12 ratings, with the consensus rating being Outperform. The average one-year price target is $312.17, indicating a potential 15.35% upside.
<h3>Comparing Ratings with Competitors</h3>
The following analysis focuses on the analyst ratings and average 1-year price targets of Globus Medical, Hologic and Masimo, three prominent industry players, providing insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Neutral trajectory for Globus Medical, with an average 1-year price target of $90.4, suggesting a potential 66.6% downside.</li>
<li>Analysts currently favor an Neutral trajectory for Hologic, with an average 1-year price target of $81.0, suggesting a potential 70.07% downside.</li>
<li>Analysts currently favor an Outperform trajectory for Masimo, with an average 1-year price target of $210.0, suggesting a potential 22.41% downside.</li>
</ul>
<h3>Comprehensive Peer Analysis Summary</h3>
The peer analysis summary offers a detailed examination of key metrics for Globus Medical, Hologic and Masimo, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Penumbra</td>
<td>Outperform</td>
<td>10.83%</td>
<td>$210.72M</td>
<td>2.99%</td>
</tr>
<tr>
<td>Globus Medical</td>
<td>Neutral</td>
<td>6.61%</td>
<td>$393.86M</td>
<td>0.64%</td>
</tr>
<tr>
<td>Hologic</td>
<td>Neutral</td>
<td>0.86%</td>
<td>$580.50M</td>
<td>4.06%</td>
</tr>
<tr>
<td>Masimo</td>
<td>Outperform</td>
<td>9.44%</td>
<td>$244.70M</td>
<td>-27.80%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Penumbra ranks highest in Revenue Growth and Gross Profit among its peers. It also has the highest Return on Equity. However, it has the lowest Consensus rating.
<h3>Unveiling the Story Behind Penumbra</h3>
Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are sold to hospitals and are developed for use by specialist physicians. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. It operates as one reportable segment and its business activity consists of the design, development, manufacturing and marketing of inventive medical products.
<h3>Penumbra's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Over the 3 months period, Penumbra showcased positive performance, achieving a revenue growth rate of 10.83% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Penumbra's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 10.68%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Penumbra's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.99% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Penumbra's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 2.24%, the company showcases efficient use of assets and strong financial health.
Debt Management: Penumbra's debt-to-equity ratio is below the industry average at 0.19, reflecting a lower dependency on debt financing and a more conservative financial approach.
<a href="https://www.benzinga.com/quote/PEN/earnings">To track all earnings releases for Penumbra visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Examining the Future: Penumbra's Earnings Outlook

Truist Securities analyst David Rescott maintains Penumbra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>) with a Buy and lowers the price target from $325 to $315.

Truist Securities Maintains Buy on Penumbra, Lowers Price Target to $315

Penumbra's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>) short percent of float has fallen 9.64% since its last report. The company recently reported that it has 1.22 million shares sold short, which is 4.5% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.96 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Penumbra Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744290025_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Penumbra has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Penumbra's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Penumbra's peer group average for short interest as a percentage of float is 4.40%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Is Penumbra Gaining or Losing Market Support?

Penumbra's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>) short percent of float has fallen 19.16% since its last report. The company recently reported that it has 1.36 million shares sold short, which is 4.98% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.02 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Penumbra Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742484619_0_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Penumbra has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Penumbra's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Penumbra's peer group average for short interest as a percentage of float is 4.07%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Peering Into Penumbra's Recent Short Interest

In the preceding three months, 14 analysts have released ratings for Penumbra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>), presenting a wide array of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Penumbra and provided 12-month price targets. The average target is $306.86, accompanied by a high estimate of $340.00 and a low estimate of $260.00. Surpassing the previous average price target of $273.91, the current average has increased by 12.03%.
<img src="https://www.benzinga.com/files/images/story/2025/1741978869_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Penumbra. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Travis Steed</td>
<td>B of A Securities</td>
<td>Announces</td>
<td>Buy</td>
<td>$320.00</td>
<td>-</td>
</tr>
<tr>
<td>Robert Marcus</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$285.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>David Rescott</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$325.00</td>
<td>$285.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$313.00</td>
<td>$285.00</td>
</tr>
<tr>
<td>Jason Mills</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$340.00</td>
<td>$323.00</td>
</tr>
<tr>
<td>Priya Sachdeva</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$320.00</td>
<td>$305.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$305.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$330.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Kallum Titchmarsh</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$260.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>David Rescott</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$328.00</td>
<td>$305.00</td>
</tr>
<tr>
<td>David Rescott</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$305.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Priya Sachdeva</td>
<td>UBS</td>
<td>Announces</td>
<td>Buy</td>
<td>$305.00</td>
<td>-</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$285.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Steve Lichtman</td>
<td>Oppenheimer</td>
<td>Announces</td>
<td>Outperform</td>
<td>$275.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Penumbra. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Penumbra compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Penumbra's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Penumbra's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PEN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Penumbra analyst ratings.</a>
<h2>Get to Know Penumbra Better</h2>
Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are sold to hospitals and are developed for use by specialist physicians. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. It operates as one reportable segment and its business activity consists of the design, development, manufacturing and marketing of inventive medical products.
<h3>Penumbra: Delving into Financials</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Penumbra displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 10.83%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 10.68%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 2.99%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Penumbra's ROA excels beyond industry benchmarks, reaching 2.24%. This signifies efficient management of assets and strong financial health.
Debt Management: Penumbra's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.19.
<h2>Analyst Ratings: Simplified</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What Analysts Are Saying About Penumbra Stock

Penumbra shares are trading higher after B of A Securities initiated coverage on the stock with a Buy rating and announced a price target of $320.

Press Releases

Penumbra, Inc. to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Penumbra, Inc. Schedules Fourth Quarter and Full Year 2024 Earnings Release and Conference Call for February 18, 2025

Penumbra, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results

Penumbra, Inc. Announces Don Kassing will Retire from Board of Directors

Seven New Data Sets Demonstrate Penumbra's Computer Assisted Vacuum Thrombectomy (CAVT) Technology Is Safe, Fast and Effective, Improves Patient Outcomes, and Delivers Healthcare Resource Benefits

Penumbra, Inc. Schedules First Quarter 2025 Earnings Release and Conference Call for April 23, 2025

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Penumbra, Inc. (NYSE: PEN)

Legal

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Penumbra, Inc. (NYSE: PEN) and Encourages Current Penumbra Shareholders to Contact the Firm

Penumbra, Inc. Reports First Quarter 2025 Financial Results

Penumbra, Inc. to Present at the BofA Securities 2025 Health Care Conference

Abbott Laboratories

Baxter Intl

Becton, Dickinson and Company Common Stock

Becton Dickinson

Boston Scientific Corporation Common Stock

Boston Scientific

DexCom

Edwards Lifesciences Corporation Common Stock

Edwards Lifesciences

GE HealthCare Technologies Inc. - Common Stock

GE HealthCare Techs

Glaukos

Globus Medical, Inc. Class A Common Stock

Globus Medical

Hologic

IDEXX Laboratories

Inspire Medical Systems, Inc. Common Stock

Inspire Medical Systems

iRhythm Technologies, Inc. - Common Stock

iRhythm Technologies

Intuitive Surgical

Integer Holdings Corporation Common Stock

Integer Holdings

Masimo

Medtronic

Koninklijke Philips N.V. NY Registry Shares

Koninklijke Philips

Insulet

ResMed

Smith & Nephew

Steris

Stryker

Teleflex

Zimmer Biomet Holdings, Inc. Common Stock

Zimmer Biomet Holdings

RBC Capital

Truist Securities

Stifel

Wells Fargo

アドバンスト マイクロ デバイセズ社 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) の株は、予想を上回る<a href="https://www.benzinga.com/news/earnings/24/07/40060832/amd-skyrockets-over-9-lifting-along-with-ai-rival-nvidia-whats-going-on">第2四半期決算</a>を受けて本日のプレマーケット取引で急騰している。
AMDは1株あたり69セントの四半期決算を報告し、これはアナリストの予想一致値である1株あたり68セントを上回った。また同社は、1株あたり5.8350億ドルの四半期売上を報告し、これはアナリストの予想一致値である1株あたり5.7240億ドルを上回った。これは<a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>のデータによるものだ。
AMDの株はプレマーケット取引で9.1％上昇し、151.01ドルになった。
以下は、プレマーケットで動いた他の銘柄の一部である。
<h3 class="wp-block-heading">上昇銘柄</h3>
<ul>
<li>Primech Holdings Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PMEC#NASDAQ">PMEC</a>) の株は、火曜日に5％以上上昇した後プレマーケット取引で114.8％上昇し、1.13ドルになった。</li>
<li>Heramba Electric plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PITA#NASDAQ">PITA</a>) の株は、火曜日に約49％下落した後、本日のプレマーケット取引で92.8％上昇し、8.29ドルになった。</li>
<li>NuZee, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUZE#NASDAQ">NUZE</a>) の株は、火曜日に約3％上昇した後、本日のプレマーケット取引で79.4％上昇し、6.64ドルになった。</li>
<li>Telesis Bio, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBIO#NASDAQ">TBIO</a>) の株は、プレマーケット取引で39.8％上昇し、5.52ドルとなった。</li>
<li>Faraday Future Intelligent Electric Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIE#NASDAQ">FFIE</a>) の株は、同社がナスダックの規制順守を回復した後、前日の取引で33.1％上昇したプレマーケット取引で0.4205ドルになった。</li>
<li>Powell Industries, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POWL#NASDAQ">POWL</a>) の株は、3四半期の決算が予想を上回った後、プレマーケット取引で25.3％上昇し、167.02ドルになった。</li>
<li>BIMI Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIMI#NASDAQ">BIMI</a>) の株は、火曜日に約66％下落した後、プレマーケット取引で22.8％上昇し、0.48ドルになった。</li>
<li>DallasNews Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DALN#NASDAQ">DALN</a>) の株は、同社が第2四半期の財務決算で前年同期比で増収を報告した後、プレマーケット取引で19.1％上昇し、3.91ドルになった。</li>
<li>Vistra Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VST#NYSE">VST</a>) の株は、同社がコマンチピーク原子力発電所の運営期間を2053年まで延長する許可を米原子力規制委員会から取得した後、プレマーケット取引で12.1％上昇し、77.35ドルになった。</li>
</ul>
<h3 class="wp-block-heading">下落銘柄</h3>
<ul>
<li>FibroGen, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGEN#NASDAQ">FGEN</a>) の株は、プレマーケット取引で40.2％下落し、0.6159ドルになった。同社は、膵臓がん患者におけるパムレブルマブの有効性と安全性を評価する2つの後期試験からの最上位結果を発表し、および転移性膵臓がん患者におけるパンブロキシマブの臨床データを報告した。</li>
<li>MacroGenics, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGNX#NASDAQ">MGNX</a>) の株は、2024年の欧州医療腫瘍学会議での2相試験のプレゼンテーションを発表した後、プレマーケット取引で24.0％下落し、3.99ドルになった。</li>
<li>Jet.AI Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JTAI#NASDAQ">JTAI</a>) の株は、ワラントに関する交換オファーと同意勧誘の結果を発表した後、プレマーケット取引で21.5％下落し、0.2631ドルになった。</li>
<li>Velo3D, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VLD#NYSE">VLD</a>) の株は、火曜日に4％下落した後、プレマーケット取引で20.6％下落し、2.20ドルになった。</li>
<li>Penumbra, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>) の株は、同社が第2四半期の決算を発表し、自社の2024会計年度の売上高予測の下方修正を行った後、プレマーケット取引で20.3％下落し、137.93ドルになった。</li>
<li>Groupon, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRPN#NASDAQ">GRPN</a>) の株は、第2四半期の一株当たり利益が予想を下回ったことを受け、プレマーケット取引で18.6％下落し、12.75ドルになった。</li>
<li>Definitive Healthcare Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DH#NASDAQ">DH</a>) の株は、NeedhamのアナリストRyan MacDonald氏が同社の投資判断を「ホールド」に継続したことにより、プレマーケット取引で17.6％下落し、4.71ドルになった。</li>
<li>O-I Glass, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OI#NYSE">OI</a>) の株は、プレマーケット取引で15.5％下落し、9.80ドルになった。同社は2024年の業績見通しを下方修正した。</li>
<li>Lemonade, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMND#NYSE">LMND</a>) の株は、四半期決算を発表した後、プレマーケット取引で14.6％下落し、19.33ドルになった。</li>
<li>Tivic Health Systems, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) の株は、火曜日に約18％下落した後、プレマーケット取引で12.4％下落し、0.5056ドルになった。</li>
</ul>

Comments

Penumbra

ニュース

最新ニュース Penumbra (NYSE:PEN) 株価情報

水曜日, 7 31, 2024

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル